Application of 2-aminonaphthylidene diazide hydrobromide to enhance bactericidal activity against Gram-negative bacteria

By using 2-Aminoperimidine as an antibiotic adjuvant, the bactericidal effect of polymyxin E is enhanced, overcoming the limitations of polymyxin E's toxicity and the problem of drug-resistant strains, thus achieving highly effective treatment against Gram-negative bacteria.

CN116617231BActive Publication Date: 2024-11-15SHENYANG PHARMA UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310687952.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-06-12
Publication Date
2024-11-15
Estimated Expiration
2043-06-12

AI Technical Summary

Technical Problem

Existing antibiotics pose safety concerns when treating drug-resistant bacterial infections. In particular, the nephrotoxicity and neurotoxicity of polymyxin E limit its dosage, resulting in limited treatment efficacy. Furthermore, the emergence of drug-resistant strains increases the difficulty of treatment.

Method used

Using 2-Aminoperimidine as an antibiotic adjuvant, the bactericidal effect of polymyxin E is enhanced by disturbing biofilms and targeting the sodium transporters of bacteria, and it can be used in combination with polymyxin E to synergistically kill Gram-negative bacteria.

Benefits of technology

2-Aminoperimidine enhances the bactericidal effect of polymyxin E, reduces its dosage requirements, expands its clinical application, reduces the emergence of drug-resistant strains, and provides an effective treatment option for drug-resistant bacteria.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GDA0005003054560000031
    Figure GDA0005003054560000031
  • Figure HDA0005003054570000011
    Figure HDA0005003054570000011
  • Figure HDA0005003054570000012
    Figure HDA0005003054570000012
Patent Text Reader

Abstract

The invention discloses an application of 2-aminonaphthobenzene hydrobromide to enhance the bactericidal effect on gram-negative bacteria, and relates to the technical field of killing gram-negative bacteria. The invention designs experiments to prove that 2-aminonaphthobenzene hydrobromide can affect the metabolic process of bacteria by destroying biofilm and inhibiting the activity of bacterial sodium transporters. 2-aminonaphthobenzene hydrobromide itself has antibacterial activity, and when it is used in combination with polymyxin E, it can enhance the bactericidal effect of polymyxin E on Escherichia coli, which fully verifies that 2-aminonaphthobenzene hydrobromide can enhance the antibiotic bactericidal effect on gram-negative bacteria. Based on the above findings, the invention provides corresponding medical uses of 2-aminonaphthobenzene hydrobromide, a bactericidal composition, a bactericidal drug, and a bactericidal method.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of killing Gram-negative bacteria, and in particular to application of 2-aminonaphthylidene diazide hydrobromide (2-Aminoperimidine) in enhancing antibiotics to kill Gram-negative bacteria. Background Art

[0002] As widely used drugs, with the widespread use of antibiotics around the world, more and more resistant and drug-resistant strains are emerging worldwide. Although antibiotics with new structures and mechanisms are constantly being developed, the treatment of bacterial infections is still a huge challenge facing the medical community. Bacteria can colonize in various organs of patients, causing different types of infectious diseases and even seriously threatening human life. In the past, polymyxin was banned due to its nephrotoxicity and neurotoxicity, but it is currently being used as a last resort for the treatment of drug-resistant bacteria. The combined use of antimicrobial drugs to treat bacterial infections is considered an effective measure to eliminate drug-resistant bacteria that cause chronic and recurrent infections. Therefore, the development of safe and effective antibiotics or antibiotic adjuvants is a promising and effective way to treat bacterial infections.

[0003] 2-Aminoperimidine is a guanidine-containing naphthalene derivative that is generally considered to be a specific inhibitor of sodium transporters, but its potential activity as an antibiotic or antibiotic adjuvant has not been reported. Summary of the invention

[0004] The present invention verifies that 2-Aminoperimidine can promote bactericidal activity by disturbing biofilms and targeting sodium transporters of bacteria, and that 2-Aminoperimidine can enhance the sensitivity of bacteria to antibiotics to achieve the effect of killing resistant bacteria and reducing the generation of drug-resistant bacteria.

[0005] Based on the experimental conclusion of the present invention, the present invention provides the use of 2-Aminoperimidine in the preparation of bactericidal drugs, and provides a bactericidal composition, a bactericidal drug and a bactericidal method.

[0006] One of the purposes of the present invention is to provide an application of 2-Aminoperimidine in preparing a drug for killing Gram-negative bacteria.

[0007] Preferably, the Gram-negative bacteria are sensitive Escherichia coli and resistant Escherichia coli.

[0008] Preferably, the drug-resistant Escherichia coli is polymyxin-resistant Escherichia coli.

[0009] Preferably, the bactericidal drug comprises polymyxin E.

[0010] The invention also provides a bactericidal composition, the components of which are a combination of antibiotics and 2-Aminoperimidine.

[0011] Preferably, the antibiotic is polymyxin E.

[0012] The present invention also provides a bactericidal drug, which targets Gram-negative bacteria. The main components of the bactericidal drug are the above-mentioned bactericidal composition and pharmaceutically acceptable excipients and carriers.

[0013] The present invention also provides a method for killing Gram-negative bacteria. The medicine used in the method is a preparation made of the above-mentioned bactericidal composition and pharmaceutically acceptable auxiliary materials.

[0014] Beneficial effects of the present invention

[0015] 1. The clinical dosage of polymyxin E is limited due to its nephrotoxicity and neurotoxicity. 2-Aminoperimidine can enhance the bactericidal effect of polymyxin E, so reducing its dosage can also achieve therapeutic effects and expand its clinical application range. In addition, 2-Aminoperimidine can reduce the production of drug-resistant bacteria.

[0016] 2.2-Aminoperimidine has the potential to be an antibiotic or antibiotic adjuvant. Its target is the bacterial sodium transporter, and the target is unreported, so it has potential application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 Survival rate graph of sensitive and resistant bacteria treated with 2-Aminoperimidine;

[0018] The growth inhibition of 2-AP on three E. coli bacteria and one P. aeruginosa bacteria.

[0019] Figure 2 Survival rate of sensitive and resistant bacteria treated with polymyxin E combined with 2-Aminoperimidine;

[0020] Growth inhibition effect of 2-AP combined with polymyxin E on the sensitive strain E. coli ATCC25922. The dark area represents a lower growth inhibition rate and a higher bacterial survival rate. A FIC index ≤ 0.5 is defined as a synergistic effect.

[0021] Figure 3 Time-kill curves of polymyxin E combined with 2-Aminoperimidine in the treatment of sensitive and resistant bacteria;

[0022] Time-kill curves of 2-AP (2.5 μg / mL), polymyxin E (0.06 μg / mL or 2 μg / mL) or their combination against the sensitive strain E. coli ATCC25922. DETAILED DESCRIPTION

[0023] The specific embodiments of the present invention will be described in detail below. In order to avoid too much unnecessary details, the well-known structures or functions will not be described in detail in the following examples. Unless otherwise defined, the technical and scientific terms used in the following examples have the same meanings as those generally understood by those skilled in the art to which the present invention belongs.

[0024] Example 1

[0025] Determination of the Minimum Inhibitory Concentration of 2-Aminoperimidine (2-AP) against E. coli and P. aeruginosa

[0026] The antimicrobial drug 2-AP was diluted 2-fold in series using liquid MH medium, and the diluted antimicrobial drug solution was added to the sterilized 96-well plate, and then the final concentration was about 1.0×10 7 The bacterial culture was incubated at 37°C for 17-24 hours, and the OD 600 The absorbance at 400 μg / mL was measured to determine the minimum inhibitory concentration (MIC) of the strain growth. The results showed that 2-AP had good antibacterial activity against the four Gram-negative bacteria. It could significantly inhibit the growth of E. coli at a concentration of only 2.5 μg / mL, and had a significant growth inhibitory effect on P. aeruginosa at a concentration of 5 μg / mL. As the concentration of 2-AP increased, the antibacterial activity against the four bacterial strains also increased (e.g. Figure 1 ), indicating that the antibacterial activity of 2-AP has a significant concentration dependence. After culturing the bacteria at 37°C for 18 hours, the MIC values ​​of 2-AP for four bacterial strains were observed, among which E. coli K12, E. coli ATCC25922, and E. coli CMCC44102 were all 20 μg / mL, and P. aeruginosa CMCC1014 was 40 μg / mL (e.g. Figure 1 ).

[0027] Example 2

[0028] Drug sensitivity test

[0029] Experiments have shown that 2-AP and colistin have a synergistic effect on sensitive strains, with an FIC index of 0.3125. For the sensitive strain E. coli ATCC25922, under the action of 1.25 μg / mL 2-AP (1 / 16 MIC), the MIC of colistin decreased 4 times from 0.5 μg / mL to 0.125 μg / mL (e.g. Figure 2 ). The above results show that 2-AP and polymyxin E have a good synergistic effect against sensitive Escherichia coli in vitro.

[0030] Table 1 FIC index of 2-AP combined with polymyxin E against sensitive strains

[0031]

[0032] Example 3

[0033] Time-kill curve experiment

[0034] The time-kill curve was used to observe the killing of bacteria by 2-AP and polymyxin E when used alone or in combination. For sensitive strains, 2-AP (2.5 μg / mL) had no bactericidal effect when used alone; 0.06 μg / mL polymyxin E had a significant bactericidal effect on sensitive strains within 12 hours, but the bactericidal effect almost disappeared at 24 hours; when the two were used in combination, the number of sensitive bacteria could be significantly reduced within 4 hours, and sensitive strains were almost completely killed at 24 hours (such as Figure 3 ). This indicates that 2-AP and polymyxin E have synergistic bactericidal activity against the sensitive strain E. coli ATCC25922 and can significantly enhance the bactericidal effect of polymyxin.

Claims

Application of a bactericidal composition of 1.2-aminonaphthylidene meta-diazine hydrobromide and polymyxin E in the preparation of a drug for killing Gram-negative bacteria.

2. The use according to claim 1, characterized in that The Gram-negative bacteria are sensitive Escherichia coli and resistant Escherichia coli.

3. The use according to claim 2, characterized in that The Gram-negative bacteria are E. coli K12, E. coli ATCC25922, and E. coli CMCC44102.

4. A bactericidal drug for Gram-negative bacteria, characterized in that: The main components of the bactericidal drug are the bactericidal composition of 2-aminonaphthylidene meta-diazine hydrobromide and polymyxin E as claimed in claim 1, and pharmaceutically acceptable excipients and carriers.